PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Immunogenicity, Vaccine”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1976

A canine parainfluenza viral vaccine: immunogenicity and safety.

A canine parainfluenza viral vaccine was developed and shown to be safe by absence of clinical disease in vaccinated dogs and by inability to isolate vaccine virus from blood or nasopharyngeal swabs. Backpassage in susceptible dogs, using blood of vaccinated dogs, could not be demonstrated. The vaccine produced neutralizing antibody when administered either intramuscularly or subcutaneously; however, a significantly higher immune response was obtained by intramuscular inoculation. Differences in the antibody response were not produced by tenfold dilutions of vaccine virus ranging from 10(2.9) to 10(5.9) median tissue culture infective doses. The presence of neutralizing antibody was associated significantly with decreased respiratory shedding period of challenge virus by vaccinated dogs compared to seronegative control dogs. Six days after aerosol exposure to virulent challenge virus, 100% of the controls (n = 5) but only 15% of the vaccinated dogs (n = 3) shed virus. Seven days after challenge exposure, virus could not be recovered from the vaccinated dogs, but 80% of the control dogs shed virus. An anamnestic response occurred in vaccinated dogs but not in the seronegative control dogs following challenge exposure. A mild clinical disease was produced in 3 of the 5 seronegative control dogs but not in the 20 vaccinated dogs.

Animals↗
PubMed1975

Recombinant WRL 105 strain live attenuated influenza vaccine. Immunogenicity, reactivity, and transmissibility.

The immunogenicity, reactivity, and transmissibility of recombinant WRL 105 (H3N2) (A/Okuda/57XA/Finland/4/74) strain live attenuated influenza virus vaccine were studied in adult male volunteers in a residential community in rural England. Thirteen volunteers received a single dose of 10(7.0) E.I.D.50 recombinant WRL 105 vaccine administered as nose drops, and twelve volunteers received placebo. Nine (82%) of eleven volunteers with initial antibody titres of less than or equal to 1/96 showed a significant antibody response to vaccination, but there was no evidence of transmission of vaccine virus to those who received placebo. The incidence and nature of reactions were similar in those who received vaccine and placebo. The vaccine was shown to confer protection against natural infection with a strain exhibition antigenic characteristics equivalent to those of A/Scotland/840/74.

Administration, Intranasal↗
PubMed1979

[Experiments for the development of a hepatitis B vaccine: immunogenicity of HBsAg in guinea pigs (author's transl)].

Hepatitis B surface antigen (HBsAg) was purified from human plasma by gel chromatography, isopyknic centrifugation, and zonal centrifugation. The final product had about 60% of the original activity and was essentially free from hepatitis B virus particles (HBV) and plasma proteins. Treatment with formaldehyde concentrations up to 0.1% for inactivation of residual infectivity did not significantly reduce antigenicity in vitro and immunogenicity in guinea pigs. Adsorption to aluminum hydroxide resulted in 16-fold higher concentrations of antibody against HBsAg (anti-HBs) than did injection of soluble HBsAg. After two injections of 0.2 microgram HBsAg, which was treated with 0.1% formaldehyde and absorbed to aluminum hydroxide, the median titer of anti-HBs in guinea pigs was 4 IU/ml (normal value in human hepatitis B convalescents: about 0.1) for 1 year without further injections. When guinea pigs received 12 equivalents of homologous anti-HBs serum before the first injection of adsorbed HBsAg, the same anti-HBs titers were found after the booster injection as in animals which had not been passively immunized. A simultaneous application of an experimental HBsAg vaccine and hepatitis B immunoglobulin would probably decrease the potential risk of HBV infections caused by the vaccine itself and also produce rapid protection. To establish absence of HBV as completely as possible, the vaccine should be produced from anti-HBe-positive plasma by efficient purification procedures and it should be inactivated by formalin.

Aluminum Hydroxide↗
PubMed1976

Influenza virus subunit vaccines. II. Immunogenicity and original antigenic sin in humans.

Subunit vaccines containing hemagglutinin, neuraminidase, and nucleocapsids of A/Port Chalmers/1/73 (H3N2) influenza virus were prepared after treatment of purified virus with ammonium deoxycholate. The immunogenicity of these subunits and the response to the common and specific antigenic determinants on the hemagglutinin subunits were studied in man. The subunits were as immunogenic in man as intact inactivated influenza virus vaccine at an equivalent concentration. Booster doses of antigen did not increase the antibody responses. Intact influenza B virus vaccine did not potentiate the immune response to the type A subunits in man. Volunteers responded differently to the common and specific determinants on the hemagglutinin subunits. The predominant antibody response was to the common or cross-reacting determinants present on hemagglutinins of both A/Hong Kong/1/68 (H3N2) and Port Chalmers/73 virus. Some men who failed to produce specific antibodies to the hemagglutinin of Port Chalmers/73 virus responded to the specific determinants on the Hong Kong/68 hemagglutinin. Higher doses of the subunit vaccines (1,400 chick cell-agglutinating units) did induce antibodies to the specific determinants on the Port Chalmers/73 virus hemagglutinin as well as to the common and specific determinants on Hong Kong/68 influenza virus.

Animals↗
PubMed1979

Comparative immunogenicity of vaccines prepared from capsular polysaccharides of group C Neisseria meningitidis O-acetyl-positive and O-acetyl-negative variants and Escherichia coli K92 in adult volunteers.

Three structurally and antigenically similar capsular polysaccharides, two derived from group C Neisseria meningitidis (O-acetyl-positive and O-acetyl-negative variants) and one from Escherichia coli K92, which cross-reacts with polysaccharide from group C N. meningitidis, were compared for their ability to induce anticapsular and bactericidal antibodies to group C N. meningitidis in adult volunteers. All three vaccines elicited group C-specific serum antibodies. The vaccine derived from the O-acetyl-negative variant was the most immunogenic of the three vaccines. With use of radiolabeled O-acetyl-positive group C N. meningitidis polysaccharide antigen, the geometric mean titers of antibody in serum were 41.7 microgram/ml to the O-acetyl-negative variant, 22.8 microgram/ml to the O-acetyl-positive variant, and 7.1 microgram/ml to E. coli K92. Antibodies induced by all three vaccines were bactericidal for both of the group C N. meningitidis polysaccharide variants. An inverse relation between the comparative immunogenicity of the O-acetyl-negative polysaccharide and the virulence of group C N. meningitidis was found.

Adult↗
PubMed1978

Clinical trial with an anti-rabies human diploid cell vaccine (HDCV).

A clinical trial with an anti-rabies human diploid cell vaccine (HDCV) Mérieux, has been carried out by the Government Central Laboratories and the District Health Office, Ministry of Health, Jerusalem, Israel, on 25 persons bitten by stray dogs and cats. These bitten persons were given 6 injections of the above-mentioned vaccine on days 0, 3, 7, 14, 30 and 90 post-exposure. A through medical examination was carried out by a qualified physician in order to establish the local and systemic side effects. These side effects were trivial and were mostly observed with the third and fourth injections. In addition a neutralization test on mice was carried out with all sera taken on the days of injection. There was a prompt and adequate development of neutralizing antibodies even on the seventh day after the beginning of treatment, and before the fourth injection. In several cases there was a very high level of neutralizing antibodies even reaching as much as 500 I.U./ml. In conclusion these results have shown that the diploid cell vaccine is a very safe immunogenic vaccine and the authors recommend its use for pre- and post-exposure.

Animals↗
PubMed1978

[Comparative study of the smallpox vaccines from B-51, EM-63 and L-IVP in a controlled epidemiological experiment. II. The characteristiics of the immunogenicity of the smallpox vaccines].

Immunogenicity of smallpox vaccines prepared of EM-63, L-IVP, and B-51 strains was studied under conditions of strict controlled epidemiological trial. Skin reactions to revaccination and vaccines antigenic activity indices were detemined in the persons vaccinated. Changes in the virus-neutralizing and antibodies suppressing hemagglutination was the same in persons vaccinated with any of the preparations tested. The maximal virus-neutralizing antibodies level was determined 1 month after the vaccination and persisted without any essential changes for one year. The titre of hemagglutination inhibiting antibodies also reached the maximum in one month, but diminished gradually by the end of one year after the vaccination. There were found no significant differences in the antigenic activity of the vaccines. The vaccines studied also displayed no difference in the number and character of skin reactions to revaccination. In comparing the antibodies level and the character of skin reactions to revaccination it was found that the titres of hemagglutination inhibiting antibodies and virus-neutralizing antibodies of 1:40 and over were in the great majority of cases determined in the blood sera of the vaccinated persons with the immediate and negative reactions to revaccination, i. e. in those with intensive postvaccinal immunity.

Antibodies, Viral↗
PubMed1978

[Immunogenic and antigenic properties of continuously cultured typhoid bacteria].

It was shown that in continuous cultivation of typhoid bacilli, by changing the rate of dilution and the regimens of carbohydrate and oxygen supply it was possible to determine conditions under which the most highly immunogenic vaccines were obtained and the maximal synthesis of antigens was observed. The regimen optimal for obtaining the highly immunogenic typhoid vaccines (D = 0.4 h-1; So = 5 g/l; pO2 = 50%) coincided with the regimen at which the maximal O-antigen synthesis was seen, and failed to coincide with the regimens necessary for the greatest synthesis of Vi- and H-antigens.

Animals↗
PubMed1979

[Evaluation of the immunogenicity of meningococcal vaccines in experiments on mice].

The immunogenicity of 2 meningococcal vaccines, multicomponent vaccine produced at the Mechnikov Research Institute for Vaccines and Sera in Moscow and polysaccharide vaccine obtained from Merck Sharp & Dohme (USA), was evaluated on experimental meningococcal sepsis in mice, produced by the injection of meningococcal culture in mucin suspension. The protective effect of these 2 vaccines, expressed in terms of ED50, was 0.28 +/- 0.12 for the multicomponent vaccine and 0.25 +/- 0.24 for the polysaccharide vaccine; the challenge dose used in the test was 10 LD50 of the culture. The multicomponent vaccine gave the maximum immunological effect in a dose of 8 micrograms, while higher or lower doses induced a lesser increase in antibody titer and thus gave lower protection to mice against infection.

Animals↗
PubMed2026

Isoform-Level Analysis Reveals Reproducible Early Changes in Transcript Usage During Human Vaccine Responses.

Vaccine-induced transcriptional responses have been extensively characterized at the gene level, but whether vaccination also alters transcript isoform usage remains largely unexplored. Here, we reanalyzed longitudinal whole-blood RNA-seq data from a discovery cohort of mRNA COVID-19 vaccine recipients using the IsoformSwitchAnalyzeR framework and validated the findings in an independent cohort. Key findings were validated by full-length RNA long-read sequencing and extended to four additional vaccine cohorts covering distinct platforms and pathogens. mRNA vaccination induced a rapid and transient wave of differential transcript usage, peaking at 24 h post-vaccination with 131 isoforms significantly altered across 107 genes, before largely resolving by Day 14. Isoform switching events were reproducible across independent cohorts and confirmed by full-length RNA long-read sequencing. Structural annotation of switching transcripts, including RMI2, WARS1, and NT5C3A, revealed changes affecting predicted protein domains and signal peptides. Notably, highly concordant isoform switching patterns were observed across MVA-based SARS-CoV-2, influenza, and Ebola vaccine cohorts and showed dose-dependent modulation. Overall, differential transcript isoform usage is a rapid and transient feature of the early human immune response to vaccination that was observed across multiple vaccine platforms. These findings reveal an underappreciated layer of transcriptional regulation that complements conventional gene-level analyses and warrants integration into future vaccine immunogenicity studies.

Humans↗
PubMed1979

Immunization of pregnant women with influenza A/New Jersey/76 virus vaccine: reactogenicity and immunogenicity in mother and infant.

The safety and immunogenicity of inactivated influenza virus vaccines in pregnant women have not been adequately investigated. In this study, 56 women received inactivated influenza A/New Jersey/76 virus vaccine during the second and third trimesters of pregnancy. No significant immediate reactions or increased fetal complications were associated with administration of the vaccine. The antibody response of the pregnant women to the vaccine was similar to that of nonpregnant adults. Forty mother-infant pairs were available for antibody surveillance. At delivery, reciprocal antibody titers of greater than or equal to 20 were present in 11 (42%) newborn (cord) sera and 15 (58%) maternal sera. Three months later, sera from only three infants (12%) contained this level of antibody. At six months, the serum of only one infant contained this level of antibody. At six months, the serum of only one infant contained detectable antibodies. Levels of passively transferred antibodies from prior maternal infection with influenza A/Victoria/75 virus also declined rapidly following birth. It is possible that immunization of pregnant women can provide sufficient protection of the newborn infants by transfer of antibodies through the placenta if (1) a more potent influenza vaccine, possibly used with booster dosing, is administered, and (2) the women deliver just prior to or during the influenza season.

Antibodies, Viral↗
PubMed1978

Pseudomonas ribosomal vaccines: preparation, properties, and immunogenicity.

The preparation, properties, and immunogenicity of ribosomal vaccines from Pseudomonas aeruginosa are described. These preparations, containing protein and RNA, were tested for immunogenicity by active immunization of mice and subsequent challenge with homologous, live bacteria. The results demonstrated that vaccines prepared from a majority of serotypes used were immunogenic, i.e., afforded 60 to 100% mouse protection against a challenge inoculum containing 8 to 50 50% lethal doses. In some cases vaccine doses as low as 1 microgram of RNA provided 100% mouse protection. Molecular sieve chromatography of a highly immunogenic ribosomal preparation on Sepharose 4B demonstrated the presence of two molecular weight fractions: (i) peak A, an excluded peak (thus having a molecular weight of at least 2 times 10(7)), and (ii) peak B, considerably retarded, with an elution position corresponding to a molecular weight of about 2.2 X 10(6), approximating that of typical 70S ribosomes. Both peaks A and B were immunogenic; however, the immunogenicity of peak A was greater (i.e., a smaller immunizing dose was required) than that of peak B. Peak A was shown to contain components of lipopolysaccharide in addition to protein and RNA (which comprised 80% of the dry weight of peak A). On the other hand, peak B was shown to be free of lipopolysaccharide, and 100% of its dry weight consisted of protein and RNA.

Animals↗
PubMed2026

Safety and Immunogenicity of Varicella Vaccination in Children and Adolescents Living With HIV: A Systematic Review.

INTRODUCTION: Preventing varicella-zoster virus infection is important in the management of human immunodeficiency virus (HIV)-positive persons. Varicella remains endemic worldwide, and HIV-positive persons can experience greater morbidity than the general population. We summarized the global literature on the safety and immunogenicity of the varicella vaccine in HIV-positive children. METHODS: Systematic review of original reports on varicella vaccination of HIV-positive children, published through December 31, 2024, including assessment of safety, immunologic responses and effectiveness after vaccination. RESULTS: Eighteen articles were analyzed. Local reactions were the most common adverse events, albeit infrequent (<21% and <10% of vaccinees after dose 1 and 2, respectively). Systemic reactions were also infrequent, consisting mostly of low-grade fever. A vaccine-related rash, reported in <5% of vaccinees, had fewer lesions and a shorter duration than typical varicella. Serious adverse events were reported only when the vaccine was inadvertently administered to children with severe HIV immunosuppression. Varicella vaccination had no clinically significant impact on plasma HIV RNA or CD4+ T-cell count after either dose. An antibody response was reported in 60%-79% of HIV-positive vaccinees after dose 2 and often declined more rapidly than in uninfected children. Cell-mediated immunity was detected in 67%-83% after dose 2. No significant differences in adverse events or short-term immune response after vaccination correlated with past or current CD4+ T-cell status. CONCLUSIONS: The varicella vaccine had a favorable safety profile and induced specific immune responses in most nonseverely immunocompromised HIV-positive children. The vaccine remains contraindicated for persons with severe HIV infection. Robust data on the durability of immune response and long-term effectiveness are needed.

Humans↗